FindTrial
Sign In

A study of adding aromatase inhibitors in the FSH stimulation cycle to reduce the impact of ovarian stimulation on the endometrium

A study of adding aromatase inhibitors in the follicle stimulating hormone (FSH) stimulation cycle to reduce the impact of ovarian stimulation on the endometrium

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-15006211
Enrollment
Unknown
Registered
2015-04-07
Start date
2015-05-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

A:The fifth day in Ovarian stimulation, add letrozole 2.5mg / day until the day of HCG injection
B:Nil

Sponsors

Reproductive & Genetic Hospital CITIC-XIANGYA
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
21 Years to 35 Years

Inclusion criteria

Inclusion criteria: Female to be aged 21 to 35 years, BMI 18 to 28, the first or the second treatment cycle; Basis FSH 1ng/l, antral follicle count (AFC) 15-23.

Exclusion criteria

Exclusion criteria: Endometriosis disease, unilateral or bilateral hydrosalpinx not blocked, uterine malformations, uterine fibroids submucosal, intramural uterine fibroids >3cm, intrauterine adhesions, unexplained uterine fluid, a history of unexplained miscarriages, the contraindications of IVF treatment

Design outcomes

Primary

MeasureTime frame
progesterone (P) levels in HCG injection day;Progestin / estrogen ratio (P / E2 ratio) in HCG injection day;—

Countries

China

Contacts

Public ContactGong Fei
lj_0305@126.com+86 13907485296

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 3, 2026